A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ROC / recurrent ovarian cancer

[Related PubMed/MEDLINE]
Total Number of Papers: 64
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ROC  (>> Co-occurring Abbreviation)
Long Form:   recurrent ovarian cancer
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. ORR, OS, PFI, PFS
2020 Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS). AGIS, CF, GHS, HRQL, PF, PPS, PPS ROC, RF, SBS, SF
2019 Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. CPS, DCR, DOR, ORR, OS, PFI, PFS, TFI
2019 Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence. HIPEC
2019 Do all patients with recurrent ovarian cancer need systemic therapy? ---
2019 PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. CA125, CI, ER, PFS, PR
2019 Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. PARPis, PFS
2019 The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients. OS, PFS, SCS
2018 A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses. AGO, AGO-OVAR, CC, MSK, SCS
10  2018 Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer. AI, ANN, CC, DFI, FIGO, OS, SCS
11  2018 HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction. eIF3a, HE4, ICS, OS, SCS, TS
12  2018 Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. GCIG-SBS, MOST, MOST-Abdo, PROM, PRR-ROC
13  2018 Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study. AEs, PLD
14  2018 Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). CRP, HRQL, mGPS, OS, PS, SBS
15  2017 A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). CBR, i.v, NOGGO, OS, TTP
16  2017 Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. HSR
17  2017 Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series. AE, CPT-Pt, CR, PR, SD, TC
18  2017 Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. OCCC, OS, PFI, PFS, PROs, TFI, TSST, TUDD
19  2017 Laparoscopic-based score assessment combined with a multiple disciplinary team in management of recurrent ovarian cancer: A single-center prospective study for personalized surgical therapy. MDT, NPV, PPV
20  2017 Optimizing treatment in recurrent epithelial ovarian cancer. ---
21  2017 Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. PFI, PFS, PR
22  2017 Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial. i.v
23  2017 Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey. PLD
24  2017 Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer. CR, OS, PFS, PR, SD
25  2017 The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience. PFS, PLD, PLD-C
26  2017 Treatment of recurrent ovarian cancer. PFI
27  2017 Treatment of recurrent ovarian cancer. PFI
28  2016 Beyond the beyond: first case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: case report. ---
29  2016 Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer. CRS, IFRT, LRFS
30  2016 Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience. PLD
31  2016 Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). CI, GC, OS, PC, PFS, PLDC, TC
32  2015 A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection. CT, RT, SCS, SeC-s
33  2015 Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. CP, OS, PFS, TFI
34  2015 Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. GC, OS, PL
35  2015 Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. HR, OS, SCR
36  2015 Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. OC
37  2015 [Recurrent ovarian cancer--qualification and results of surgical treatment]. PFS
38  2014 Computed tomography-guided 125I seed interstitial implantation in the treatment of recurrent ovarian cancer. CT
39  2014 Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. DeltaCA125, PFS
40  2014 Limitations to the use of carboplatin-based therapy in advanced ovarian cancer. ---
41  2014 Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. ORR, OS, PFS, PLD
42  2014 Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. OS, PFI, PFS, PLD, PPS, PR, PS
43  2014 Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients. ---
44  2014 Real-life experience using trabectedin plus pegylated liposomal doxorubicin combination to treat patients with relapsed ovarian cancer. PLD
45  2014 The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. AEs, DC, MST
46  2013 The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). GCIG, PFS
47  2013 Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. 24-h_q3w
48  2012 Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. CP, PFS
49  2012 Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. CP, OS
50  2012 Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications. i.p
51  2012 Walking a tightrope: oncologists' perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter. OC
52  2012 Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). CI, GINECO, HR, PFS
53  2011 Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. CTCAE, GCIG, GIP, PLD, RECIST
54  2011 Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. AUC, C-PLD, CALYPSO, CP, GCIG
55  2010 It's a choice to move forward: women's perceptions about treatment decision making in recurrent ovarian cancer. TDM
56  2010 Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. AUC, CP, PFS, PLD
57  2010 Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. PLD
58  2009 Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer? IT
59  2009 Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). NOGGO, VTE
60  2008 Second-line randomized trials in epithelial ovarian cancer. cCR
61  2008 Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study. TFI
62  2007 A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. PFS, PLD
63  2005 The role of surgery in recurrent ovarian cancer. CS, ECOG
64  2003 Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. ---